scholarly journals Oncologic Outcomes of Radical Prostatectomy and High-Dose Intensity-Modulated Radiotherapy with Androgen-Deprivation Therapy for Relatively Young Patients with Unfavorable Intermediate-Risk Prostate Adenocarcinoma

Cancers ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1517
Author(s):  
Szu-Yuan Wu ◽  
Shyh-Chyi Chang ◽  
Chang-I Chen ◽  
Chung-Chien Huang

Purpose: To estimate the oncologic outcomes of radical prostatectomy (RP) and high-dose intensity-modulated radiotherapy (IMRT) with short-term androgen-deprivation therapy (ADT) in relatively young men with unfavorable intermediate-risk prostate cancer, as defined by the National Comprehensive Cancer Network (NCCN-UIR-PC). Patients and Methods: We enrolled relatively young men (≤65 years) from the Taiwan Cancer Registry who had been diagnosed as having NCCN-UIR-PC and who had received RP or high-dose IMRT (at least ≥72 Gy) with short-term ADT (4–6 months). After propensity score matching of the confounders, Cox proportional regression was used to model the time from the index date (i.e., date of diagnosis) to all-cause death, biochemical failure (BF), locoregional recurrence (LRR), and distant metastasis (DM). Results: The corresponding adjusted hazard ratios (95% confidence intervals) of the risk of all-cause death, BF, LRR, and DM were 2.76 (1.36–5.60, p = 0.0050), 2.74 (1.72–4.84, p < 0.0001), 1.28 (1.09–1.90, p = 0.0324), and 2.11 (1.40–4.88, p = 0.0052), respectively. Conclusions: RP is superior to high-dose IMRT with short-term ADT in terms of oncologic outcomes for relatively young men with UIR-PC.

2009 ◽  
Vol 56 (4) ◽  
pp. 669-677 ◽  
Author(s):  
Piet Ost ◽  
Valérie Fonteyne ◽  
Geert Villeirs ◽  
Nicolaas Lumen ◽  
Willem Oosterlinck ◽  
...  

Urology ◽  
2012 ◽  
Vol 80 (2) ◽  
pp. 337-342 ◽  
Author(s):  
Lanea M.M. Keller ◽  
Mark K. Buyyounouski ◽  
Dennis Sopka ◽  
Karen Ruth ◽  
Tracy Klayton ◽  
...  

2016 ◽  
Vol 157 (20) ◽  
pp. 776-788
Author(s):  
Antal Tamás Zemplényi ◽  
László Mangel ◽  
Zoltán Kaló ◽  
Dóra Endrei ◽  
Szimonetta Lohner ◽  
...  

Introduction: One of the most relevant focus of recent developments in radiotherapy technology was the adequate irradiation of prostate cancer. Aim: The aim of this study was to analyse the safety of normo- and hypofractionated and high dose intensity-modulated radiotherapy. Method: Toxicities were identified through literature review and evidence was synthetized with meta-analytical methods. Results: The use of high dose intensity-modulated radiotherapy resulted in no difference in severe genitourinary (acute p = 0.9; late p = 0.95) and moderate or severe gastrointestinal (acute: N/A; late: p = 0.08) toxicities compared to 3D conformal radiation therapy. The risk ratio of moderate acute (RR = 1.39, 95% CI: 1.09–1.78; p = 0.008) and late genitourinary toxicities (RR = 1.48, 95% CI: 1.26–1.75; p<0,00001) was higher. There was no difference in hypo- and normofractionated intensity-modulated radiotherapy regarding severe genitourinary (acute: N/A; late: p = 0.73) and moderate or severe gastrointestinal (acute: p = 0.73; late: p = 0.55) toxicities, the risk of late moderate genitourinary toxicities was higher when using hypofractionation scheme (RR = 1.39, 95% CI: 1.00–1.94; p = 0.05). Conclusions: The use of normo- and hypofractionated and high dose intensity-modulated radiotherapy proved to be safe. However the higher risk of moderate genitourinary adverse events require an extensive clinical risk estimation. Orv. Hetil., 2016, 157(20), 776–788.


Sign in / Sign up

Export Citation Format

Share Document